Please login to the form below
tislelizumab
This page shows the latest tislelizumab news and features for those working in and with pharma, biotech and healthcare.
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
This is our fifth positive phase 3 readout for tislelizumab, which we are developing broadly as a potentially differentiated anti-PD-1 antibody. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung
Latest news
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
months in the tislelizumab arm compared to 11.9 months in the docetaxel arm. ... Finally, the median duration of response (DoR) in the tislelizumab arm and docetaxel arm was 13.5 months and 6.2 months, respectively.
-
Boehringer Ingelheim to manufacture first biologic in China under new reforms
The milestone was achieved thanks to Boehringer’s collaboration with Chinese pharma company BeiGene, which included Boehringer offering manufacturing capabilities to support the launch of its monoclonal antibody tislelizumab. ... BeiGene's PD-1
-
China updates drug reimbursement list, agrees price cuts
This therapy is also under regulatory review in China and Europe for the same indication, and the company is also developing its own PD-1 inhibitor – tislelizumab – which has been filed
-
BeiGene bags FDA approval for first product Brukinsa in lymphoma
BeiGene is also developing PD-1 inhibitor tislelizumab – which has been filed for approval in China for classical Hodgkin’s lymphoma – and pamiparib, a PARP 1/2 inhibitor for ovarian cancer.
-
BeiGene gets speedy US review for lymphoma drug zanubrutinib
In addition to zanubrutinib, BeiGene is also developing PD-1 inhibitor tislelizumab – which has been filed for approval in China for classical Hodgkin’s lymphoma – and pamiparib, a PARP 1/2
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and ... Tislelizumab is in global phase III trials in a number of tumour
-
Biopharma's Future: Made in China
It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- First von Willebrand disease therapy heads new FDA approvals
- Sanofi to buy acne specialist Origimm
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- David Hunt launches independent agency The Considered
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
